Dr. Joshua Clayton, a 29-year-old radiology resident at
Baylor University Medical Center in Dallas, wanted to learn about his ancestry.
So he sent a sample of his saliva to 23andMe, the genetic testing company.
His report was pretty mundane — no new revelations. But then
he sent the profile created by 23andMe to a separate company called
Promethease, which promises to do a more in-depth analysis for genetic
mutations that cause disease.
The news was not good. Dr. Clayton got back a report with a
sinister red box at the top saying he had a mutation linked to Lynch syndrome,
a frightening genetic disorder that leads to potentially deadly cancers at an
early age.
In an interview, Dr. Clayton said he “knew, at least
cursorily, that false positives were common with these tests.” But “that didn’t
change the frightened feelings or concern, because I certainly couldn’t blow it
off.”
After two weeks of panic and yet another genetic test at a
company with expertise in medical diagnostics, he learned the red box result
was wrong. He simply didn’t have the mutation.
More Americans are embracing consumer genetic testing, but
the Food and Drug Administration limits what major firms like 23andMe or
Ancestry.com can say about a consumer’s health.
So many people are taking an additional step: uploading all
the raw data created by these companies
to second companies for additional analysis. But these are not firms
certified to provide medical diagnoses, nor are they sophisticated academic
centers.
Companies like Promethease warn customers not to regard
their results as medical diagnoses. Mostly, they are comparing a consumer’s raw
data to gene variants reported to be linked to disease.
But it’s not at all clear that consumers understand how
uncertain their results may be.
There are no systematic studies of how often the
direct-to-consumer results and third-party analyses are wrong. In one small
study, Ambry Genetics — a lab certified to do medical testing — looked at 49
samples sent in by physicians whose patients had been told that they had
disease-causing mutations by third-party interpreters.
Ambry found that 40 percent were wrong. In addition, some
genetic variations classified by second companies as threatening actually were
benign.
This tiny sample doesn’t prove that the false-positive rate
is 40 percent. But patients like Dr. Clayton are not uncommon, genetic
counselors say. And they are increasingly worried about the flip side: false
negatives that reassure consumers who actually should be worried.
Dr. Judy Garber, director of the Center for Cancer Genetics
and Prevention at the Dana-Farber Cancer Institute in Boston, said one of her
patients was told by a consumer testing company she had Li-Fraumeni syndrome,
which greatly raises the risk of a number of
rare cancers.
Further testing showed that diagnosis was wrong. “It makes
you worry about the people who don’t come in,” said Dr. Garber.
“People think they are getting the same kind of genetic
testing as they would get from a certified clinical laboratory,” said Stephany
Tandy-Connor, a genetic counselor at Ambry. “Nothing could be further from the
truth.”
Even some doctors are misled by the reports, she said.
Of course, companies like Ambry have an interest in making
sure their business is not usurped by consumer testing firms. But it’s also
true that the method used by consumer companies is very different from those
used by certified clinical laboratories.
Consumer companies method look for changes in tiny segments
of genes, rather than examining the entire gene and looking for alterations.
That is cheap but not comprehensive.
And because they are not making medical diagnoses, these
companies are not subject to the sort of quality controls as certified labs,
which require extensive confirmation that results are free of errors.
Compounding the problem, the second companies rely on
databases that may contain errors — so even if the genetic alteration found by
the first company is correct, the analysis can be wrong. Ambry found such
patients in its recent analysis.
Greg Lennon, a co-founder of Promethease, said that the
company’s reports include a disclaimer saying the data are “not intended for
medical or health purposes.” Customers are warned to seek out “an independent,
clinically validated test” if they are told of a mutation and to seek out a
genetic counselor.
When errors occur, they usually derive from mistakes in the
raw DNA data, said Mike Cariaso, also a co-founder of Promethease.
23andMe offers limited medical testing — for example,
looking for three of the most common mutations in breast cancer genes that
occur mostly in Ashkenazi Jews. But there are thousands of other alterations in
those genes that the company does not track.
The F.D.A. has given 23andMe approval to do similar testing
for 10 disorders linked to genetic mutations, but not for the huge number of
others, including Lynch syndrome, that companies like Promethease look for.
The variations in DNA in 23andMe’s raw data “are not for
medical or diagnostic use,” said Shirley Wu, the company’s director of product
science. “The data hasn’t undergone the same kind of quality control and
validation as our variations in our health reports.”
https://www.nytimes.com/2018/07/02/health/gene-testing-disease-nyt.html
Courtesy of a colleague
Courtesy of a colleague
No comments:
Post a Comment